Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and ...

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Increases speed to market for drug developers working on nucleic acid therapeutics.

Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. The San Diego company has guided for full-year revenue ...

After years of restructuring, Chicago-based Exicure has South Korean majority ownership and is buying the U.S. arm of a South ...

Ultima Genomics, Inc., a developer of an ultra-high throughput next-generation sequencing (NGS) platform, today announced that its UG 100™ was selected as the sequencing platform to enable UK ...

The Company also announced that it plans to announce its fourth quarter and full year 2024 financial and operating results after the market closes on Tuesday, February 25, 2025, and will host a ...

The UK Biobank project, announced today, aims to investigate how fluctuations in protein levels during mid- to late-life may influence <a target= ...